



DEPARTMENT OF HEALTH & HUMAN SERVICES

National Institutes of Health
Bethesda, Maryland 20892

July 18, 2017

J. Donald Easton, M.D.
Clinical Professor
UCSF Department of Neurology
Sandler Neurosciences Center
675 Nelson Rising Lane
San Francisco, CA 94158-0663

Dear Dr. Easton:

I am writing to confirm that the NINDS-appointed Data and Safety Monitoring Board (DSMB) for your clinical trial, "Platelet-Oriented Inhibition in New TIA and minor ischemic stroke" (POINT), met in Chicago, IL on June 30, 2017 to review all available data from the trial. The DSMB had no concerns regarding safety or study implementation, and thus recommended the trial proceed as planned.

The next meeting or teleconference of the DSMB will be scheduled for December 2017.

Sincerely,

A handwritten signature in black ink, appearing to read "Peter R. Gilbert", with a stylized flourish at the end.

Peter R. Gilbert, Sc.M.
Clinical Research Project Manager
Division of Clinical Research
National Institute of Neurological Disorders and Stroke